Get the Stockscreener App
75.09
0.08%
-0.06
After Hours:
75.09
Hologic Inc stock is traded at $75.09, with a volume of 1.62M.
It is down -0.08% in the last 24 hours and up +0.29% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$75.15
Open:
$75.18
24h Volume:
1.62M
Relative Volume:
0.59
Market Cap:
$16.76B
Revenue:
$4.04B
Net Income/Loss:
$557.10M
P/E Ratio:
31.16
EPS:
2.4102
Net Cash Flow:
$916.70M
1W Performance:
+0.67%
1M Performance:
+0.29%
6M Performance:
+10.44%
1Y Performance:
+16.47%
1-Day Range:
$75.06
$75.26
1-Week Range:
$74.67
$75.26
52-Week Range:
$51.90
$75.36
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
75.09 | 16.78B | 4.04B | 557.10M | 916.70M | 2.4102 |
|
ISRG
Intuitive Surgical Inc
|
496.12 | 175.84B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
180.62 | 48.87B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
79.39 | 39.53B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
259.62 | 38.39B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
45.04 | 37.69B | 27.43B | 1.27B | 1.01B | 1.5829 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Downgrade | Argus | Buy → Hold |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-21-25 | Downgrade | BNP Paribas Exane | Outperform → Neutral |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-18-25 | Upgrade | Argus | Hold → Buy |
| Aug-06-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-27-25 | Reiterated | Needham | Hold |
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
Hologic, Inc. $HOLX Shares Sold by Allianz Asset Management GmbH - MarketBeat
China regulator approves Blackstone, TPG acquisition of medtech firm Hologic - Reuters
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Is Wall Street Bullish or Bearish on Hologic Stock? - Yahoo Finance
Is Hologic (HOLX) Pricing Reflect Its Cash Flow Strength After Recent Stability In Diagnostics? - simplywall.st
Azzad Asset Management Inc. ADV Trims Position in Hologic, Inc. $HOLX - MarketBeat
Bone Mineral Densitometry (BMD) Market is expected to reach US$ - openPR.com
China approves Blackstone, TPG acquisition of medtech firm Hologic - The Economic Times
China market regulator: approved Blackstone and TPG's acquisition of medical technology company Hologic - marketscreener.com
Market Fear: Whats the profit margin of Hologic Inc2025 Technical Patterns & Smart Swing Trading Alerts - baoquankhu1.vn
Twin Capital Management Inc. Cuts Position in Hologic, Inc. $HOLX - MarketBeat
Nuance Investments LLC Sells 1,017,410 Shares of Hologic, Inc. $HOLX - MarketBeat
US Market Recap: Does Hologic Inc have a sustainable dividendJuly 2025 Opening Moves & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Hologic, Inc. $HOLX Holdings Cut by IQ EQ FUND MANAGEMENT IRELAND Ltd - MarketBeat
Hologic, Inc. (HOLX) Announces Shareholder Approval for Merger w - GuruFocus
Hologic Shareholders Approve Blackstone and TPG Buyout Deal - TipRanks
SA's Competition Commission approves proposed deal whereby Hopper parent intends to buy Hologic, without conditions - marketscreener.com
Hologic’s Aptima assay secures FDA approval for HPV primary screening - Medical Device Network
Machina Capital S.A.S. Buys 13,426 Shares of Hologic, Inc. $HOLX - MarketBeat
Hologic’s Aptima HPV assay receives FDA approval for primary screening By Investing.com - Investing.com Nigeria
Hologic Goes Global: Can International Expansion Offset China and Africa Headwinds? - Smartkarma
FDA Approves Hologic’s Aptima HPV Assay Primary Screening Option - Medical Product Outsourcing
Hologic receives FDA approval for Aptima® HPV assay primary screening option, expanding cervical health portfolio - marketscreener.com
Hologic Says US FDA Approves Aptima HPV Testing Assay - marketscreener.com
Hologic’s Aptima HPV assay receives FDA approval for primary screening - Investing.com
Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health PortfolioHologic, Inc. - Hologic, Inc. - Investor Relations
Hologic Receives FDA Approval for Aptima HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio - Business Wire
Analysts Have Conflicting Sentiments on These Healthcare Companies: Hologic (HOLX) and Irhythm Technologies (IRTC) - The Globe and Mail
United States Bone Densitometer Devices Market is expected - openPR.com
National Pension Service Grows Position in Hologic, Inc. $HOLX - MarketBeat
New York State Common Retirement Fund Grows Stock Holdings in Hologic, Inc. $HOLX - MarketBeat
Robert Olstein's Strategic Moves: Exiting Hologic Inc with a -1.44% Impact - Yahoo Finance
OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - GlobeNewswire Inc.
Hologic, Inc. (HOLX) is attracting investor attention: Here is what you should know - MSN
Hologic (HOLX) International Revenue Performance Explored - Yahoo Finance
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Hologic, Inc. (HOLX) Stock Analysis: Unpacking Growth Potential Amidst a Hold Rating Consensus - DirectorsTalk Interviews
Is Hologic Inc vulnerable to short sellersMarket Activity Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
(HOLX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Market Outlook: What are analysts price targets for Hologic Inc2025 Price Momentum & Weekly Top Performers Watchlists - baoquankhu1.vn
Hologic (HOLX) Q1 2026 Margin Compression Reinforces Cautious Community Narratives - Sahm
Evercore ISI Adjusts Hologic Price Target to $76 From $78, Maintains In Line Rating - marketscreener.com
Hologic Q1 comes up short of Street expectations ahead of sale to private equity - MassDevice
HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash - TradingView
Decoding Hologic Inc (HOLX): A Strategic SWOT Insight - GuruFocus
Compared to Estimates, Hologic (HOLX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Hologic (NASDAQ:HOLX) Misses Q4 CY2025 Revenue Estimates - Finviz
Hologic (HOLX) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance
Setup Watch: Does Hologic Inc have a sustainable dividendForecast Cut & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Hologic: Fiscal First Quarter Earnings Overview - Bitget
Hologic (HOLX) Faces Legal Challenges Amid Merger and Product Re - GuruFocus
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.81%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):